We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+5.57%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$1.88B
AUM Growth
-$278M
Cap. Flow
-$105M
Cap. Flow %
-5.61%
Top 10 Hldgs %
47.5%
Holding
84
New
5
Increased
6
Reduced
10
Closed
11

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$42.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$39.9M
3
PRTA icon
Prothena Corp
PRTA
+$19.3M
4
IMVT icon
Immunovant
IMVT
+$17M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$13.6M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$146M
2
ETNB
89bio
ETNB
+$39.8M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$32.5M
4
CABA icon
Cabaletta Bio
CABA
+$6.97M
5
IRON icon
Disc Medicine
IRON
+$5.77M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRON icon
76
Disc Medicine
IRON
$2.94B
– –
-130,000
Closed -$5.77M
LITS
77
Lite Strategy Inc
LITS
$32.8M
– –
-145,654
Closed -$958K
MREO
78
Mereo BioPharma
MREO
$54.7M
– –
-2,250,000
Closed -$2.97M
RNAC icon
79
Cartesian Therapeutics
RNAC
$229M
– –
-109,469
Closed -$3.68M
VERU icon
80
Veru
VERU
$36M
– –
-34,730
Closed -$413K
KNTE
81
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
– –
-491,000
Closed -$1.49M
RETA
82
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-1,430,004
Closed -$146M
ISEE
83
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-825,000
Closed -$32.5M
BLCM
84
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-450,000
Closed -$167K
1 2 3
4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2023 Portfolio in Review

As of Q3 2023, Boxer Capital held 84 positions worth $1.88B, down 13% from $2.16B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Boxer Capital withdrew a net $105M in Q3 2023, closing 11 positions and reducing 10 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital opened a new position in State Street SPDR S&P Biotech ETF worth $36.5M.

  • Boxer Capital's largest Q3 2023 buy was State Street SPDR S&P Biotech ETF: 500,000 shares worth $36.5M.
  • Boxer Capital added most to Mirati Therapeutics, Inc. Common Stock in Q3 2023, an estimated $42.9M increase.
  • Boxer Capital's biggest Q3 2023 reduction was Black Diamond Therapeutics, cutting an estimated $5.56M.
  • Boxer Capital fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $146M.
  • Boxer Capital's ten largest holdings make up 47% of its $1.88B portfolio in Q3 2023.
  • Boxer Capital opened 5 new positions and closed 11 in Q3 2023.
  • Boxer Capital's portfolio value fell 13% quarter-over-quarter to $1.88B.

Based on Boxer Capital's 13F filing for Q3 2023, filed 14 Nov 2023.